Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Elanco Animal Health Incorporated (NYSE:ELAN) has been given an average recommendation of “Moderate Buy” by the thirteen brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $28.20.

A number of analysts have issued reports on ELAN shares. KeyCorp boosted their price objective on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday. JPMorgan Chase & Co. upped their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Finally, Morgan Stanley upped their price target on shares of Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $21.77 on Monday. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $10.87 billion, a P/E ratio of -43.54, a P/E/G ratio of 2.34 and a beta of 1.69. Elanco Animal Health has a 12-month low of $12.40 and a 12-month high of $27.72. The firm has a 50-day moving average price of $23.02 and a two-hundred day moving average price of $23.28.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The business’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Analysts anticipate that Elanco Animal Health will post 1.11 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Rajeev A. Modi purchased 4,911 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was bought at an average price of $20.35 per share, with a total value of $99,938.85. Following the acquisition, the insider owned 160,812 shares in the company, valued at approximately $3,272,524.20. The trade was a 3.15% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were purchased at an average cost of $20.09 per share, with a total value of $99,867.39. Following the acquisition, the chief executive officer owned 171,971 shares in the company, valued at $3,454,897.39. This trade represents a 2.98% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 1.14% of the company’s stock.

Institutional Trading of Elanco Animal Health

Institutional investors and hedge funds have recently made changes to their positions in the company. NewEdge Advisors LLC lifted its holdings in shares of Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after acquiring an additional 627 shares during the period. Root Financial Partners LLC increased its position in Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after purchasing an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. acquired a new position in Elanco Animal Health during the 4th quarter worth approximately $41,000. Huntington National Bank increased its position in Elanco Animal Health by 136.7% during the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after purchasing an additional 1,087 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. increased its position in Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after purchasing an additional 900 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.